The sad news came this week of the death of a young girl who started a movement, one which has exposed again the built-in strains of how the dietary supplement market is regulated in the United States.
The US Food and Drug Administration has issued an additional six warning letters in recent days on coronavirus claims. The letters coincide with an industry coalition raising a red flag on the growing flood of such claims on dietary supplement-type products.
A coalition of dietary supplement industry trade associations have come out in support of FDA actions against fraudulent coronavirus treatment claims and have urged retailers to not stock products with such claims on their labels.
Industry experts have slammed statements made in a recent JAMA Viewpoint that called for probiotics to be regulated to the same standard as drugs, and decried the “paucity of high-quality data supporting the value of probiotics”.
The National Advertising Division has directed Church & Dwight to stop making a claim of better absorption on its line of gummy vitamins. The company has responded by appealing the decision to a review board.
The $2 trillion stimulus packaged passed unanimously by the US Senate this morning will have important implications for the dietary supplement industry that may help companies survive the worst of the coronavirus crisis impacts.
Synthetic astaxanthin product developer Cardax has released a white paper and reportedly filed a patent application on the ingredient’s antiviral properties and in publicizing the fact has treaded on the disease claim line according to legal experts.
In light of the ongoing novel Coronavirus (COVID19) public health emergency, IPA World Congress + Probiota Americas has been postponed until November 16-18, 2020 at the Crystal Gateway Marriott Hotel, Washington DC.